FLT3 and aortic valve disorder: By targeting FLT3 protein and inhibiting FLT3 phosphorylation, ATL I can inhibit the activation of PI3K/AKT pathway, reduce the production of HIF1-α, and inhibit the osteogenic differentiation of VIC, which has the effect of treating calcified aortic valve disease [82].